Glucosylceramide synthase modulation ameliorates murine renal pathologies and promotes macrophage effector function in vitro.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
02 Aug 2024
Historique:
received: 01 02 2024
accepted: 19 07 2024
medline: 3 8 2024
pubmed: 3 8 2024
entrez: 2 8 2024
Statut: epublish

Résumé

While significant advances have been made in understanding renal pathophysiology, less is known about the role of glycosphingolipid (GSL) metabolism in driving organ dysfunction. Here, we used a small molecule inhibitor of glucosylceramide synthase to modulate GSL levels in three mouse models of distinct renal pathologies: Alport syndrome (Col4a3 KO), polycystic kidney disease (Nek8

Identifiants

pubmed: 39095617
doi: 10.1038/s42003-024-06606-7
pii: 10.1038/s42003-024-06606-7
doi:

Substances chimiques

Glucosyltransferases EC 2.4.1.-
ceramide glucosyltransferase EC 2.4.1.80

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

932

Informations de copyright

© 2024. The Author(s).

Références

Romagnani, P. Chronic kidney disease. Nat. Rev. 3, 17088 (2017).
Zhang, T., de Waard, A. A., Wuhrer, M. & Spaapen, R. M. The role of glycosphingolipids in immune cell functions. Front. Immunol. 10, 90 (2019).
pubmed: 30761148 pmcid: 6361815 doi: 10.3389/fimmu.2019.00090
D'Angelo, G., Capasso, S., Sticco, L. & Russo, D. Glycosphingolipids: synthesis and functions. FEBS J. 280, 6338–6353 (2013).
pubmed: 24165035 doi: 10.1111/febs.12559
Zhu, Y. et al. Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineage. J. Biol. Chem. 286, 14787–14794 (2011).
pubmed: 21402703 pmcid: 3083190 doi: 10.1074/jbc.M111.218610
Tsai, B., Gilbert, J. M., Stehle, T. & Lencer, W. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J. 22, 4346–4355 (2003).
pubmed: 12941687 pmcid: 202381 doi: 10.1093/emboj/cdg439
Takenouchi, H. & Kiyokawa, N. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J. Cell Sci. 117, 3911–3922 (2004).
pubmed: 15265987 doi: 10.1242/jcs.01246
Nakayama, H. et al. The regulatory roles of glycosphingolipid-enriched lipid rafts in immune systems. FEBS Lett. 592, 3921–3942 (2018).
pubmed: 30320884 doi: 10.1002/1873-3468.13275
Breiden, B. & Sandhoff, K. Lysosomal glycosphingolipid storage diseases. Annu. Rev. Biochem. 88, 461–485 (2019).
pubmed: 31220974 doi: 10.1146/annurev-biochem-013118-111518
Alam, S., Fedier, A., Kohler, R. S. & Jacob, F. Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids. Glycobiology 25, 351–356 (2015).
pubmed: 25715344 doi: 10.1093/glycob/cwu187
Jimbo, M. & Yamagishi, K. Development of a new inhibitor of glucosylceramide synthase. J. Biochem. 127, 485–491 (2000).
pubmed: 10731721 doi: 10.1093/oxfordjournals.jbchem.a022631
Natoli, T. A., Smith, L. A. & Rogers, K. A. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med. 16, 788–792 (2010).
pubmed: 20562878 pmcid: 3660226 doi: 10.1038/nm.2171
Blumenreich, S. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease. J. Neurochem. 156, 692–701 (2021).
pubmed: 32743826 doi: 10.1111/jnc.15136
Viel, C. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci. Rep. 11, 20945 (2021).
pubmed: 34686711 pmcid: 8536659 doi: 10.1038/s41598-021-00404-5
Anuraga, G. & Wang, W. J. Potential prognostic biomarkers of NIMA (never in mitosis, gene a)-related kinase (NEK) family members in breast cancer. J. Pers. Med. 11, 1089 (2021).
pubmed: 34834441 pmcid: 8625415 doi: 10.3390/jpm11111089
Smith, L. A. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. JASN 17, 2821–2831 (2006).
pubmed: 16928806 doi: 10.1681/ASN.2006020136
Sardi, S. P. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. PNAS 114, 2699–2704 (2017).
pubmed: 28223512 pmcid: 5347608 doi: 10.1073/pnas.1616152114
Cosgrove, D. et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev. 10, 2981–2992 (1996).
pubmed: 8956999 doi: 10.1101/gad.10.23.2981
Andrews, K. L. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am. J. Pathol. 160, 721–730 (2002).
pubmed: 11839593 pmcid: 1850644 doi: 10.1016/S0002-9440(10)64892-4
Mollet, G. & Ratelade, J. Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome. JASN 20, 2181–2189 (2009).
pubmed: 19713307 pmcid: 2754108 doi: 10.1681/ASN.2009040379
Ding, W., Yousefi, K. & Goncalves, S. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight 3, e94818 (2018).
pubmed: 29563333 pmcid: 5926939 doi: 10.1172/jci.insight.94818
Zalli, D. The Nek8 protein kinase, mutated in the human cystic kidney disease nephronophthisis, is both activated and degraded during ciliogenesis. Hum. Mol. Genet. 21, 1155–1171 (2012).
pubmed: 22106379 doi: 10.1093/hmg/ddr544
Lehtonen, S. & Jalanko, H. Nephrin trafficking beyond the kidney—role in glucose–stimulated insulin secretion in β cells. JASN 27, 965–968 (2016).
pubmed: 26400568 doi: 10.1681/ASN.2015080960
Chen, E. Y. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).
pubmed: 23586463 pmcid: 3637064 doi: 10.1186/1471-2105-14-128
Kuleshov, M. V. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Xie, Z. Gene set knowledge discovery with enrichr. Curr. Protoc. 1, e90 (2021).
pubmed: 33780170 pmcid: 8152575 doi: 10.1002/cpz1.90
Jang, H. S. & Kim, J. I. Bone marrow-derived cells play a major role in kidney fibrosis via proliferation and differentiation in the infiltrated site. Biochim. Biophys. Acta 1832, 817–825 (2013).
pubmed: 23466592 doi: 10.1016/j.bbadis.2013.02.016
Mobarak, E. Glucosylceramide modifies the LPS-induced inflammatory response in macrophages and the orientation of the LPS/TLR4 complex in silico. Sci. Rep. 8, 13600 (2018).
pubmed: 30206272 pmcid: 6134110 doi: 10.1038/s41598-018-31926-0
Soto-Heredero, G. et al. Glycolysis – a key player in the inflammatory response. FEBS J. 287, 3350–3369 (2020).
pubmed: 32255251 pmcid: 7496292 doi: 10.1111/febs.15327
Guiteras, R. Macrophage in chronic kidney disease. Clin. Kidney J. 9, 765–771 (2016).
pubmed: 27994852 pmcid: 5162417 doi: 10.1093/ckj/sfw096
Li, X. A Tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat. Med. 14, 863–868 (2008).
pubmed: 18552856 pmcid: 3359869 doi: 10.1038/nm1783
Zheng, D. et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. JASN 14, 2588–2595 (2003).
pubmed: 14514736 doi: 10.1097/01.ASN.0000088720.61783.19
Bieniaś, B. Early markers of tubulointerstitial fibrosis in children with idiopathic nephrotic syndrome: preliminary report. Med. (Baltim.) 94, e1746 (2015).
doi: 10.1097/MD.0000000000001746
Warady, B. A. Alport syndrome classification and management. Kidney Med. 2, 639–649 (2020).
pubmed: 33094278 pmcid: 7568086 doi: 10.1016/j.xkme.2020.05.014
Stathem, M. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels. J. Cell. Biochem. 116, 67–80 (2015).
pubmed: 25145677 pmcid: 4229434 doi: 10.1002/jcb.24943
Wang, H. NEK1-mediated retromer trafficking promotes blood–brain barrier integrity by regulating glucose metabolism and RIPK1 activation. Nat. Commun. 12, 4826 (2021).
pubmed: 34376696 pmcid: 8355301 doi: 10.1038/s41467-021-25157-7
Zhang, Y. & Wang, S. Identification of monocytes associated with severe COVID-19 in the PBMCs of severely infected patients through single-cell transcriptome sequencing. Engineering 17, 161–169 (2021).
pubmed: 34150352 doi: 10.1016/j.eng.2021.05.009
Liu, Y. Ganglioside depletion and EGF responses of human GM3 synthase-deficient fibroblasts. Glycobiology 18, 593–601 (2008).
pubmed: 18480157 doi: 10.1093/glycob/cwn039
Sharma, D. K. Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol. Biol. Cell 15, 3114–3122 (2004).
pubmed: 15107466 pmcid: 452569 doi: 10.1091/mbc.e04-03-0189
Jennemann, R. Glycosphingolipids are essential for intestinal endocytic function. J. Biol. Chem. 287, 32598–32616 (2012).
pubmed: 22851168 pmcid: 3463339 doi: 10.1074/jbc.M112.371005
Gao P. Mitochondria-associated endoplasmic reticulum membranes (MAMs) and their prospective roles in kidney disease. Oxid. Med Cell. Longev. https://doi.org/10.1155/2020/3120539 (2020).
Batta, G. Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease. Sci. Rep. 8, 157 (2018).
pubmed: 29317695 pmcid: 5760709 doi: 10.1038/s41598-017-18405-8
Lingwood, C. A. Glycosphingolipid functions. Cold Spring Harb. Perspect. Biol. 3, a004788 (2011).
pubmed: 21555406 pmcid: 3119914 doi: 10.1101/cshperspect.a004788
Parker, M. I., Nikonova, A. S., Sun, D. & Golemis, E. A. Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease. Cell. Signal. 67, 109497 (2020).
pubmed: 31830556 doi: 10.1016/j.cellsig.2019.109497
Wilson, P. D. Apico-basal polarity in polycystic kidney disease epithelia. Biochim. Biophys. Acta 1812, 1239–1248 (2011).
pubmed: 21658447 doi: 10.1016/j.bbadis.2011.05.008
Andersson, L. Glucosylceramide synthase deficiency in the heart compromises β1-adrenergic receptor trafficking. Eur. Heart J. 42, 4481–4492 (2021).
pubmed: 34297830 pmcid: 8599074 doi: 10.1093/eurheartj/ehab412
Atala, A., Freeman, M. R. & Mandell, J. Juvenile cystic kidneys (jck): a new mouse mutation which causes polycystic kidneys. Kidney Int. 43, 1081–1085 (1993).
pubmed: 8510385 doi: 10.1038/ki.1993.151
Gomez, I. G. Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Investig. 125, 141–156 (2015).
pubmed: 25415439 doi: 10.1172/JCI75852
Roselli, S. Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol. Cell. Biol. 24, 550–560 (2004).
pubmed: 14701729 pmcid: 343810 doi: 10.1128/MCB.24.2.550-560.2004
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Liberzon, A. & Subramanian, A. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
pubmed: 21546393 pmcid: 3106198 doi: 10.1093/bioinformatics/btr260
Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Finak, G., McDavid, A. & Yajima, M. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).
pubmed: 26653891 pmcid: 4676162 doi: 10.1186/s13059-015-0844-5
Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).
pubmed: 28991892 pmcid: 5937676 doi: 10.1038/nmeth.4463
Kanehisa, M. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
pubmed: 10592173 pmcid: 102409 doi: 10.1093/nar/28.1.27
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951 (2019).
pubmed: 31441146 pmcid: 6798127 doi: 10.1002/pro.3715
Kanehisa, M. et al. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545–D551 (2021).
pubmed: 33125081 doi: 10.1093/nar/gkaa970
Wu, C. C. Integrative analysis of DiseaseLand omics database for disease signatures and treatments: a bipolar case study. Front. Genet. 10, 396 (2019).
pubmed: 31114610 pmcid: 6503737 doi: 10.3389/fgene.2019.00396
Korotkevich, G. et al. Fast gene set enrichment analysis. bioRxiv, https://www.biorxiv.org/content/10.1101/060012v3 (2021).
Durinck, S. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21, 3439–3440 (2005).
pubmed: 16082012 doi: 10.1093/bioinformatics/bti525
Durinck, S. Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomaRt. Nat. Protoc. 4, 1184–1191 (2009).
pubmed: 19617889 pmcid: 3159387 doi: 10.1038/nprot.2009.97
Muto, Y. Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis. Nat. Commun. 13, 6497 (2022).
pubmed: 36310237 pmcid: 9618568 doi: 10.1038/s41467-022-34255-z
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8

Auteurs

Agnes Cheong (A)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA. agnes.cheong@sanofi.com.

Florin Craciun (F)

Genomics Medicine Unit, Sanofi, Waltham, MA, USA.

Hervé Husson (H)

Genomics Medicine Unit, Sanofi, Waltham, MA, USA.

Joseph Gans (J)

Translational Sciences, Sanofi, Cambridge, MA, USA.

Javier Escobedo (J)

Genomics Medicine Unit, Sanofi, Waltham, MA, USA.

Yi-Chien Chang (YC)

Translational Sciences, Sanofi, Cambridge, MA, USA.

Lilu Guo (L)

Translational Sciences, Sanofi, Cambridge, MA, USA.

Mariana Goncalves (M)

Translational Sciences, Sanofi, Cambridge, MA, USA.

Nathan Kaplan (N)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Laurie A Smith (LA)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Sarah Moreno (S)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Joseph Boulanger (J)

Research and Development Business Office, Sanofi, Cambridge, MA, USA.

Shiguang Liu (S)

Rare Diseases and Rare Blood Disorders Research, Sanofi, Cambridge, MA, USA.

Jacqueline Saleh (J)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Mindy Zhang (M)

Translational Sciences, Sanofi, Cambridge, MA, USA.

Anna S Blazier (AS)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Weiliang Qiu (W)

Non-Clinical Efficacy & Safety, Sanofi, Cambridge, MA, USA.

Andrew Macklin (A)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Tejaswi Iyyanki (T)

Precision Medicine and Computational Biology, Sanofi, Cambridge, MA, USA.

Clément Chatelain (C)

Precision Medicine and Computational Biology, Sanofi, Cambridge, MA, USA.

Shameer Khader (S)

Precision Medicine and Computational Biology, Sanofi, Cambridge, MA, USA.

Thomas A Natoli (TA)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Oxana Ibraghimov-Beskrovnaya (O)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Dimitry Ofengeim (D)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA.

Jonathan D Proto (JD)

Rare and Neurologic Diseases Research, Sanofi, Cambridge, MA, USA. jproto@neurocrine.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH